Gillian McGovern, Associate Editor

BATURA demonstrated that albuterol/budesonide significantly reduced severe exacerbation risk reduction in patients with mild asthma.

Patients with newly diagnosed transplant-eligible multiple myeloma (NDTE-MM) had high rates of complete response and minimal residual disease–negativity.

Interim trial data presented at the 2025 World Conference on Lung Cancer shows pumitamig’s promising efficacy in patients with extensive stage small cell lung cancer (ES-SCLC).

The approval is supported by clinical findings from the EMBER-3 trial.

The authors wrote that patients with CKD who are younger than 60 years may be at a greater risk of depression.

Recent studies reveal that simvastatin does not enhance escitalopram's effects in treating depression, despite improving metabolic health in obese patients.

Hercessi shows promising efficacy and safety in treating HER2+ metastatic breast cancer (MBC), with no significant risks from switching from Herceptin.

The indication is for the treatment of adult and pediatric patients who weigh at least 30 kg.

The approval is supported by findings from the MK-3475A-D77 study.

Additionally, the FDA granted a provisional interchangeability designation to both biosimilars.

Cemiplimab was also superior in improving progression-free survival, objective response rate, and duration of response in patients with non–small cell lung cancer (NSCLC).

In a recent study, machine learning demonstrated its ability to predict progression to end-stage renal disease among patients with chronic kidney disease (CKD).

When combined with an anti–PD-L1 therapy, tarlatamab significantly improves overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

A panel of 4 experts discussed the most favored nation (MFN) initiative and its impacts on research and development, market and payer distributions, and pharmacists and patients.

The findings were presented at the 2025 American Heart Association Hypertension Scientific Sessions and published in the Journal of the American Society of Nephrology.

Patients with inflammatory bowel disease (IBD) who switched to the biosimilar reported adverse events, but these are believed to stem from health anxiety.

Investigators emphasize that early cardiovascular risk assessments and preventive strategies are necessary for women with polycystic ovarian syndrome (PCOS).

The treatment was generally well-tolerated in patients with ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC).

The 2 abstracts, which were presented at the European Society of Cardiology 2025 Congress, utilized data from the CDC WONDER database.

Pavblu, a biosimilar to Eylea, also showed no clinically meaningful differences in efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).

A chief pharmacy officer emphasizes the vital role of pharmacists in enhancing patient care, advocating for recognition, and integration within health care systems.

Compared with docetaxel, adagrasib shows significant progression-free survival (PFS) benefits in patients with non–small cell lung cancer (NSCLC).

FDA approves a new extended-release suspension formulation of risperidone for schizophrenia, expanding treatment options for patients.

Compared with rivaroxaban, abelacimab significantly lowered bleeding risk in patients with atrial fibrillation regardless of kidney function.

This decision is believed to redefine how biological drugs will be developed, approved, and made affordable for patients.

The approval of 2 denosumab biosimilars, Bildyos and Bilprevda, enhances access to affordable bone health treatments for patients.

The subcutaneous injection for maintenance treatment enhances accessibility and reduces infusion time for patients.

Future research should focus on optimizing drug design, mitochondrial biogenesis regulation, and establishment of treatments for acute kidney injury (AKI).

The action is supported by 3 ongoing clinical trials, which are evaluating izalontamab brengitecan (iza-bren) in non–small cell lung cancer (NSCLC) and other diseases.

The FDA updated sparsentan's REMS, easing monitoring requirements, enhancing treatment access for IgA nephropathy patients, and supporting kidney function preservation.